1. Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA: Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 1982, Suppl: 3430s-3433s.
2. Gale KE, Anderson JW, Tormey DC, Mansour EG, Davis TE, Horton J, Wolter JM, Smith TJ, Cummings FJ: Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 1994, 12: 1630-1638.
3. Perez Carrion R, Alberola Candel V, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol. 1994, Suppl 7: 19-24.
4. Thurlimann B, Beretta K, Bacchi M: First-line fadrozole HCI (CGS-16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol. 1996, 7: 471-479.
5. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomised, cross-over study. J Clin Oncol. 2002, 20: 751-757. 10.1200/JCO.20.3.751.